A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma

International Journal of Cancer

Volumn 118, Issue 8, 2006, Pages 1992-1997

  Takenoyama, Mitsuhiro ^a   Baurain, Jean Françis ^b,c   Yasuda, Manabu ^a   So, Tomoko ^a   Sugaya, Masakazu ^a   Hanagiri, Takeshi ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a   Boon, Thierry ^b,d   Coulie, Pierre G ^b,e  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b DE DUVE INSTITUTE   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CTL; Lung cancer; Mutation; NF YC

Indexed keywords

HLA B ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF Y; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE; MELANOMA; NFYC GENE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CCAAT-BINDING FACTOR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 33645239336     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21594     Document Type: Article

References (38)

1. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. Cancer Immunity 2001, http://www.cancerimmunity. org/peptidedatabase/Tcellepitopes.htm.
2. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
3. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-84.
4. (+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004;64:1595-99.
5. V599EBRaf. Cancer Res 2004;64:5456-60.
6. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
7. Slingluff CL, Cox AL, Stover JM, Jr, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994;54:2731-37.
8. Weynants P, Thonnard J, Marchand M, Deloos M, Boon T, Coulie PG. Derivation of tumor-specific cytolytic T cell clones from two lung cancer patients with long survival. Am J Resp Crit Care Med 1999;159:55-62.
9. Karanikas V, Colau D, Baurain J-F, Chiari R, Thonnard J, Guttierez I, Goffinet C, Van Schaftingen E, Weynants P, Boon T, Coulie PG. High frequency of CTL directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718-24.
10. Takenoyama M, Yoshino I, Eifuku R, So T, Imahayashi S, Sugaya M, Yasuda M, Inoue M, Ichiyoshi Y, Osaki T, Nagashima A, Nomoto K, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 2001;92:309-15.
11. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-90.
12. Takenoyama M, Yoshino M, Fujie H, Hanagiri T, Yoshimatsu T, Imabayashi S, Eifuku R, Nomoto K, Yasumoto K. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res 1998;89:60-66.
13. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain J-F, Karanikas V, Chouaib S, Coulie PG. A point mutation in the a-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001;61:4078-83.
14. Yoshino I, Takenoyama M, Fujie H, Hanagiri T, Yoshimatsu T, Imabayashi S, Eifuku R, Ogami A, Yano K, Osaki T, Nakanishi R, Ichiyoshi Y, et al. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer. Jpn J Cancer Res 1997;88:743-9.
15. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
16. Maity SN, de Crombrugghe B. Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem Sci 1998;23:174-78.
17. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999;239:15-27.
18. Bucher P. Weight matrix descriptions of four eukaryotic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J Mol Biol 1990;212:563-78.
19. Liang SG, Maity SN. Pathway of complex formation between DNA and three subunits of CBF/NF-Y. Photocross-linking analysis of DNA-protein interaction and characterization of equilibrium steps of subunit interaction and DNA binding. J Biol Chem 1998;273:31590-98.
20. Zemzoumi K, Frontini M, Bellorini M, Mantovani R. NF-Y histone fold alpha1 helices help impart CCAAT specificity. J Mol Biol 1999;286:327-37.
21. Romier C, Cocchiarella F, Mantovani R, Moras D. The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y. J Biol Chem 2003;278:1336-45.
22. Liberati C, di Silvio A, Ottolenghi S, Mantovani R. NF-Y binding to twin CCAAT boxes: role of Q-rich domains and histone fold helices. J Mol Biol 1999;285(4):1441-55.
23. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999;274:29677-82.
24. Korner K, Jerome V, Schmidt T, Muller R. Cell cycle regulation of the murine cdc25B promoter: essential role for nuclear factor-Y and a proximal repressor element. J Biol Chem 2001;276(13):9662-9.
25. Frontini M, Imbriano C, Manni I, Mantovani R. Cell cycle regulation of NF-YC nuclear localization. Cell Cycle 2004;3:217-22.
26. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004;101(Suppl. 2):14631-38.
27. Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, Ellefsen K, Valmori D, Liénard D, Plum J, MacDonald HR, Speiser DE, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002;195:485-94.
28. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Coulie PG. High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-48.
29. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303.
30. Baurain J-F, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG. High frequency of autologous anti-melanoma CTLs directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000;164:6057-66.
31. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999;29:592-601.
32. Sensi M, Nicolini G, Zanon M, Colombo C, Molla A, Bersani I, Lupetti R, Parmiani G, Anichini A. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res 2005;65(2):632-40.
33. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97(9):4760-5.
34. Echchakir H, Vergnon I, Dorothee G, Grunenwald D, Chouaib S, Mami-Chouaib F. Evidence for in situ expansion of diverse antitumor specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol 2000;12:537-46.
35. Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249-57.
36. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004;25:131-34.
37. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002;62:3971-79.
38. Weynants P, Lethé B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 1994;56:826-29.